Levit

Levit

levetiracetam

Manufacturer:

InnoGen Pharmaceuticals

Distributor:

InnoGen Pharmaceuticals
Full Prescribing Info
Contents
Levetiracetam.
Description
Each film-coated tablet contains: Levetiracetam 500 mg.
Levetiracetam is an analogue of Piracetam, Levetiracetam acts on the CNS and has been described as a 'nootropic'; it is said to protect the cerebral cortex against hypoxia. It is also reported in inhibit platelet aggregation and reduce blood viscosity at high doses.
Action
Pharmacology: Pharmacokinetics: Levetiracetam is readily absorbed from the gastrointestinal tract and peak plasma concentrations are usually achieved within 1.3 hours of oral administration and steady-state achieved after 2 days. Levetiracetam is not extensively metabolized; approximately 25% of the dose is metabolized by hydroxylation and the metabolites are inactive. About 95% of a dose is excreted as unchanged drug and metabolites in the urine. Plasma protein binding is minimal. The plasma elimination half-life has been reported to be about 7 hours.
Indications/Uses
Levetiracetam is used as adjunctive therapy in the treatment of partial seizures with or without secondary generalization.
Dosage/Direction for Use
The initial dose of Levetiracetam is 1 g on the first day of treatment in two divided doses. Thereafter the daily dose may be increased in increments of 1 g every 2 to 4 weeks until effective antiepileptic control is achieved, up to a maximum dose of 3 g daily or as prescribed by the physician. As with other antiepileptics, withdrawal of Levetiracetam therapy or transition to or from another type of antiepileptic therapy should be made gradually to avoid precipitating an increase in the frequency of seizures.
Special Precautions
Levetiracetam should be used with caution in renal impairment; dosage reduction in patients with reduced renal function or those undergoing haemodialysis. Renal function should also be assessed in patients with severe hepatic impairment, and the dose adjusted accordingly.
Adverse Reactions
The most commonly reported adverse effects associated with Levetiracetam are somnolence, weakness, and dizziness. Anorexia, diarrhea, dyspepsia, nausea, ataxia, headache, amnesia, depression, emotional liability, insomnia, aggression, nervousness, tremor, vertigo, diplopia and rash may occur less frequently.
Storage
Store at temperatures not exceeding 30°C.
MIMS Class
ATC Classification
N03AX14 - levetiracetam ; Belongs to the class of other antiepileptics.
Presentation/Packing
FC tab 500 mg x 60's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in